These blocking antibodies inhibit the interaction of CTLA-4 or PD-1 receptors on T-cells with their ligands on tumor cells or antigen-presenting cells and can reinvigorate tumor-reactive T-cells that have become dysfunctional or exhausted in the immunosuppressive tumor microenvironment3,4. Here, CTLA4 is linked to neoplasm.